Abstract:Introduction: Targeting CD19, a significant surface marker of B cell malignant cells, with anti-CD19/CD3 bispecific antibodies became new choices in B cell hematological malignancies. Blinatumomab as the first generation CD19/CD3 bispecific antibody (bsAb) was approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. However, it also has its own limitations, including side effects and limited efficacy. Bruton tyrosine kinase (BTK) inhibitor, ibrutinib has been shown to inhibit the IL-2-induced tyrosine kinase (ITK) which expressed in T and NK cells. This inhibition could result in modulation of cytokine production by T cells. Here we reported a newly designed CD19/CD3 bispecific antibody (A-319) with similar mechanism of action as blinatumomab. To further improve the efficacy and reduce side effects, we tried to combine ibrutinib with A-319, and explore the biological effects and the mechanisms of enhanced efficacy and reduced CRS in vitro and in vivo. Methods: A-319 was provided by ITabMed Ltd (Shanghai, China). CFSE was used to evaluate the proliferation of T cells, and CD25/CD69 staining was applied to assess the activation of T cells induced by A-319. Supernatant from co-cultured tumor and T cells was collected and measured for lactate dehydrogenase (LDH) lysis to measure cytotoxicity. Humanized mice model were built by human PBMC injection into NOG mice. To build CRS model, we allowed Raji derived tumor to grow up to 600-800mm3, at which point we dosed mice with high dose A-319(20μg/kg). Tube formation assay using HUVEC cells was performed to explore the effects of ibrutinib on angiogenesis. Results: A-319 effectively induced CD19-positive tumor cell lysis. The regression analysis presented a significant correlation between CD19 expression of target cells and the sensitivity to A-319 (p < 0.01). Exposure T cells to A-319 enhanced T cell proliferation and promoted T cell activation (CD25+CD69+T cells) significantly. Moreover, A-319 produced remarkable anti-tumor effects in vivo though companied by CRS. Interestingly, the addition of ibrutinib inhibited A-319 induced CRS and improve the anti-tumor efficacy in vitro and in vivo. Experiments exploring the mechanisms of the combined effects showed that ibrutinib could inhibit the infiltration of M2 (CD163, Arg-1) macrophage and normalize vascular (CD34+α-SMA+) in vivo compared with A-319. The in vitro results also presented that ibrutinib could polarize macrophage into M1 (CD80, CD86, iNOS). Tube formation assay on HUVEC cells proved that ibrutinib could inhibit macrophage mediated tube formation. Keywords: Tumor Biology and Heterogeneity, Combination Therapies, Immunotherapy No conflicts of interests pertinent to the abstract.

Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)

Psychological Effects During Reduced Training in Distance Runners*

High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab

[Annual changes in the testicular activity of hybrid ducks resulting from crossing Pekin males (Anas platyrhynchos L.) and barbarie females (Cairina moschata L.)].

Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma

Targeted Alpha Therapy with [225Ac]Ac-Macropa-Isatuximab for CD38-positive Hematological Malignancies

Novel Anti-Cd20 Antibody Tgla with Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity Mediates Potent Anti-Lymphoma Activity

Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment

Experimental and Numerical investigation of hot-jet ignition with shock effects in a constant-volume combustor

Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies

Effect of AVM0703 treatment on the limitations of R-CHOP and survival in a model applicable to ABC subtype DLBCL.

Antitumor Effects of Nonconjugated Murine Lym-2 and Human-Mouse Chimeric Cll-1 Monoclonal Antibodies Against Various Human Lymphoma Cell Lines in Vitro and in Vivo

THE CD19/CD3 BISPECIFIC ANTIBODY WORK EFFECTIVELY AS ADJUNCT WITH IBRUTINIB ON THE TREATMENT OF B‐CELL LYMPHOMA

Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy

High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma

Effect of 67Cu-2It-bat-lym-1 Therapy on BCL-2 Gene and Protein Expression in a Lymphoma Mouse Model.

A Low Complexity Sparse Code Multiple Access Detector Based on Stochastic Computing

Anti-CD20 treatment for B-cell malignancies: current status and future directions

Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile